3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
43
Carcinoma, Hepatocellular
19
Rectal Neoplasms
10
Colonic Neoplasms
10
Neoplasm Metastasis
9
Gastrointestinal Stromal Tumors
8
Sarcoma
5
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Melanoma
4
Pancreatic Neoplasms
3
Osteosarcoma
3
Liver Neoplasms
3
Glioblastoma
3
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Interventions
lenvatinib
3
Fluorouracil
3
Drug Therapy
3
Oxaliplatin
2
Leucovorin
2
Gemcitabine
2
Folfox protocol
2
Floxuridine
2
regorafenib
1
gemcitabine-oxaliplatin regimen
1
durvalumab
1
donafenib
1
apatinib
1
Surgical Procedures, Operative
1
Radiotherapy
1
Dexamethasone
1
Cryosurgery
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cirrhosis, Familial, with Pulmonary Hypertension
×
regorafenib
×
Clear all
NCT06946849
2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
76 enrolled